Search Results
Jun 10, 2026, 10:09 ET Dispensary of Hope Launches "Hope Alliance" Campaign with Support from Amneal Pharmaceuticals
time, which is the foundation of long-term health and stability."About Amneal PharmaceuticalsAmneal Pharmaceuticals, Inc. (NASDAQ: AMRX) is a U.S.-based biopharmaceutical company committed to making healthy possible. Through its broad portfolio of generic, specialty, biosimilar and injectable
More news about: Dispensary of Hope
Feb 13, 2026, 11:26 ET Accessible Health Platforms Gain Scale Across $6T Health and Wellness Market
systems[2]. Five companies operating along that accessibility curve include Doseology Sciences (CSE: MOOD), Amneal Pharmaceuticals (NASDAQ: AMRX), Prestige Consumer Healthcare (NYSE: PBH), Viking Therapeutics (NASDAQ: VKTX), and Insulet (NASDAQ: PODD).
More news about: Equity Insider
Jan 27, 2026, 18:02 ET TTM Technologies, Dutch Bros, Advanced Energy Industries, and American Healthcare REIT Set to Join S&P MidCap 400; Others to Join S&P SmallCap 600
TTM Technologies Inc. (NASD: TTMI) will replace Civitas Resources Inc. (NYSE: CIVI) in the S&P MidCap 400, and Amneal Pharmaceuticals Inc. (NASD: AMRX) will replace TTM Technologies in the S&P SmallCap 600 effective prior to the opening of trading on Friday, January 30. S&P SmallCap 600 constituent
More news about: S&P Dow Jones Indices
Dec 22, 2025, 16:00 ET mAbxience und Amneal geben FDA-Zulassung für Denosumab-Biosimilars unter Bezugnahme auf Prolia® und XGEVA® bekannt
und teilweise im Besitz von Insud Pharma befindliche Unternehmensgruppe, und Amneal Pharmaceuticals, Inc. („Amneal" oder das „Unternehmen") (NASDAQ: AMRX) gaben heute bekannt, dass die US-amerikanische Arzneimittelbehörde FDA (Food and Drug Administration) ihre Anträge auf Zulassung von Biologika (BLAs)
More news about: mAbxience
Dec 22, 2025, 16:00 ET mAbxience e Amneal annunciano l'approvazione da parte della FDA dei biosimilari di denosumab con riferimento a Prolia® e XGEVA®
gruppo controllato da Fresenius Kabi con partecipazione parziale di Insud Pharma, e Amneal Pharmaceuticals, Inc. ("Amneal" o la "Società") (NASDAQ: AMRX), hanno annunciato oggi che la Food and Drug Administration (FDA) statunitense ha approvato le loro domande di autorizzazione all'immissione in commercio
More news about: mAbxience
Dec 22, 2025, 16:00 ET mAbxience y Amneal anuncian la aprobación de la FDA de biosimilares de denosumab referidos a Prolia® y XGEVA®
participado mayoritariamente por Fresenius Kabi y parcialmente por Insud Pharma, y Amneal Pharmaceuticals, Inc. («Amneal» o la «Compañía») (NASDAQ: AMRX), han anunciado hoy que la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) ha aprobado sus solicitudes
More news about: mAbxience
Dec 22, 2025, 16:00 ET mAbxience et Amneal annoncent l'autorisation par la FDA des biosimilaires du denosumab référencés Prolia® et XGEVA®
détenu majoritairement par Fresenius Kabi et partiellement par Insud Pharma, et Amneal Pharmaceuticals, Inc. (« Amneal » ou « la Société ») (NASDAQ : AMRX), ont annoncé aujourd'hui que la Food and Drug Administration (FDA) américaine avait approuvé leurs demandes d'autorisation de mise sur le marché (BLA)
More news about: mAbxience